Selectively Generic | Value Research Ajanta Pharma’s entry into the US & EU markets is likely to be its key growth driver…
Stock Analyst Choice

Selectively Generic

Ajanta Pharma’s entry into the US & EU markets is likely to be its key growth driver…

As part of our Wealth Creator Series , today we look at Ajanta Pharma. This is one of the 39 stocks that were short-listed that passed through our stringent stock screen filters.

Focus on select generics has rewarded Ajanta Pharma with healthy margins whereas entry into the regulated markets of US and EU is likely to be the key growth driver for the company. Ajanta also operates a US FDA approved manufacturing facility at Aurangabad. A debt equity ratio of 0.6 will support its ambitious capex plans of Rs 390 crore in the next two years and the management expects to add Rs 1,000 crore to its topline by FY15.




To read about how we arrived at the list click here. To read about stocks from the Wealth Creator List, click here.






Other Categories